452 related articles for article (PubMed ID: 27659679)
1. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.
Fredman G; Hellmann J; Proto JD; Kuriakose G; Colas RA; Dorweiler B; Connolly ES; Solomon R; Jones DM; Heyer EJ; Spite M; Tabas I
Nat Commun; 2016 Sep; 7():12859. PubMed ID: 27659679
[TBL] [Abstract][Full Text] [Related]
2. Acute Coronary Syndrome May be Associated with Decreased Resolvin D1-to-Leukotriene B4 Ratio.
Sun C; Zheng W; Liang L; Zhang Z; Liu Z; Sun W; Zhou J; Qiao W; Xie Q; Tang R
Int Heart J; 2023 Mar; 64(1):22-27. PubMed ID: 36682769
[TBL] [Abstract][Full Text] [Related]
3. Resolvin D1 promotes efferocytosis in aging by limiting senescent cell-induced MerTK cleavage.
Rymut N; Heinz J; Sadhu S; Hosseini Z; Riley CO; Marinello M; Maloney J; MacNamara KC; Spite M; Fredman G
FASEB J; 2020 Jan; 34(1):597-609. PubMed ID: 31914705
[TBL] [Abstract][Full Text] [Related]
4. MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis.
Cai B; Thorp EB; Doran AC; Sansbury BE; Daemen MJ; Dorweiler B; Spite M; Fredman G; Tabas I
J Clin Invest; 2017 Feb; 127(2):564-568. PubMed ID: 28067670
[TBL] [Abstract][Full Text] [Related]
5. Pre-eclampsia is associated with reduced resolvin D1 and maresin 1 to leukotriene B4 ratios in the plasma.
Oliveira Perucci L; Pereira Santos TA; Campi Santos P; Ribeiro Teixeira LC; Nessralla Alpoim P; Braga Gomes K; Pires Sousa L; Sant'Ana Dusse LM; Talvani A
Am J Reprod Immunol; 2020 Feb; 83(2):e13206. PubMed ID: 31679164
[TBL] [Abstract][Full Text] [Related]
6. The role of non-resolving inflammation in atherosclerosis.
Kasikara C; Doran AC; Cai B; Tabas I
J Clin Invest; 2018 Jul; 128(7):2713-2723. PubMed ID: 30108191
[TBL] [Abstract][Full Text] [Related]
7. Resolvin D1 Enhances Necroptotic Cell Clearance Through Promoting Macrophage Fatty Acid Oxidation and Oxidative Phosphorylation.
Hosseini Z; Marinello M; Decker C; Sansbury BE; Sadhu S; Gerlach BD; Bossardi Ramos R; Adam AP; Spite M; Fredman G
Arterioscler Thromb Vasc Biol; 2021 Mar; 41(3):1062-1075. PubMed ID: 33472399
[TBL] [Abstract][Full Text] [Related]
8. Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice.
Viola JR; Lemnitzer P; Jansen Y; Csaba G; Winter C; Neideck C; Silvestre-Roig C; Dittmar G; Döring Y; Drechsler M; Weber C; Zimmer R; Cenac N; Soehnlein O
Circ Res; 2016 Oct; 119(9):1030-1038. PubMed ID: 27531933
[TBL] [Abstract][Full Text] [Related]
9. Resolvin D1 promotes the targeting and clearance of necroptotic cells.
Gerlach BD; Marinello M; Heinz J; Rymut N; Sansbury BE; Riley CO; Sadhu S; Hosseini Z; Kojima Y; Tang DD; Leeper NJ; Spite M; Barroso M; Rayner KJ; Fredman G
Cell Death Differ; 2020 Feb; 27(2):525-539. PubMed ID: 31222041
[TBL] [Abstract][Full Text] [Related]
10. Low salivary resolvin D1 to leukotriene B
Thul S; Labat C; Temmar M; Benetos A; Bäck M
Eur J Prev Cardiol; 2017 Jun; 24(9):903-906. PubMed ID: 28195518
[TBL] [Abstract][Full Text] [Related]
11. Unexpected Role of MPO-Oxidized LDLs in Atherosclerosis: In between Inflammation and Its Resolution.
Tangeten C; Zouaoui Boudjeltia K; Delporte C; Van Antwerpen P; Korpak K
Antioxidants (Basel); 2022 Apr; 11(5):. PubMed ID: 35624738
[TBL] [Abstract][Full Text] [Related]
12. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities.
Bäck M; Yurdagul A; Tabas I; Öörni K; Kovanen PT
Nat Rev Cardiol; 2019 Jul; 16(7):389-406. PubMed ID: 30846875
[TBL] [Abstract][Full Text] [Related]
13. Pro-resolution therapeutics for cardiovascular diseases.
Heinz J; Marinello M; Fredman G
Prostaglandins Other Lipid Mediat; 2017 Sep; 132():12-16. PubMed ID: 28450270
[TBL] [Abstract][Full Text] [Related]
14. 2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular-Cellular Mechanisms in the Progression of Atherosclerosis.
Tabas I
Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):183-189. PubMed ID: 27979856
[TBL] [Abstract][Full Text] [Related]
15. Associations Between Resolvin D1 and Culprit Plaque Morphologies: An Optical Coherence Tomography Study in Patients with ST-Segment Elevation Myocardial Infarction.
Chen R; Li J; Sheng Z; Zhou J; Wang Y; Zhao X; Li N; Liu W; Liu C; Zhou P; Chen Y; Yan S; Song L; Yan H; Zhao H
J Inflamm Res; 2023; 16():6457-6467. PubMed ID: 38164164
[TBL] [Abstract][Full Text] [Related]
16. Pro-resolving lipid mediators in the resolution of neointimal hyperplasia pathogenesis in atherosclerotic diseases.
Satish M; Agrawal DK
Expert Rev Cardiovasc Ther; 2019 Mar; 17(3):177-184. PubMed ID: 30582389
[TBL] [Abstract][Full Text] [Related]
17. Resolvin D1-mediated NOX2 inactivation rescues macrophages undertaking efferocytosis from oxidative stress-induced apoptosis.
Lee HN; Surh YJ
Biochem Pharmacol; 2013 Sep; 86(6):759-69. PubMed ID: 23856291
[TBL] [Abstract][Full Text] [Related]
18. Tissue factor targeting peptide enhances nanoparticle binding and delivery of a synthetic specialized pro-resolving lipid mediator to injured arteries.
Levy ES; Kim AS; Werlin E; Chen M; Sansbury BE; Spite M; Desai TA; Conte MS
JVS Vasc Sci; 2023; 4():100126. PubMed ID: 38045567
[TBL] [Abstract][Full Text] [Related]
19. Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators-What is the Evidence so far?
Schebb NH; Kühn H; Kahnt AS; Rund KM; O'Donnell VB; Flamand N; Peters-Golden M; Jakobsson PJ; Weylandt KH; Rohwer N; Murphy RC; Geisslinger G; FitzGerald GA; Hanson J; Dahlgren C; Alnouri MW; Offermanns S; Steinhilber D
Front Pharmacol; 2022; 13():838782. PubMed ID: 35308198
[TBL] [Abstract][Full Text] [Related]
20. Distinct Analgesic Actions of DHA and DHA-Derived Specialized Pro-Resolving Mediators on Post-operative Pain After Bone Fracture in Mice.
Zhang L; Terrando N; Xu ZZ; Bang S; Jordt SE; Maixner W; Serhan CN; Ji RR
Front Pharmacol; 2018; 9():412. PubMed ID: 29765320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
